Symbio Confirms Treakisym’s In-House Commercialization Post Patent Expiration in 2020e
Significantly reduces execution risk for an operational turnaround in 2021e As highlighted in previous notes ("Symbio Pharma (4582 JP) - Gross...
258 Views
Smartkarma’s Week that Was in JP/KR: King Street Vs. Toshiba, Korea's Donki, and SKT Split
Below is the list of the Japan/Korea related posts put on the Smartkarma platform last week. It was a holiday week for both Japan and Korea. So, we...
354 Views
Treakisym to Be Used as a Pre-Treatment To CAR-T Therapy
Announcement – Symbio Pharmaceuticals (4582 JP) on September 27, 2018, announced that it has filed a partial change application for marketing...
732 Views
Growth Drivers on Track – Operational Turnaround Expected in 2021
We reiterate our “Overweight” rating on the stock post 1H FY18 (YE Dec-18) earnings1H FY18 Results Highlights Symbio reported an increase in 1H...
376 Views
Symbio Pharma (4582 JP) - Gross Margin Expansion Led Operational Turnaround in 2021
2020 – an inflection point for Symbio Treakisym (bendamustine), Symbio’s only revenue driver currently, is marketed by Eisai in Japan for r/r NHL....
140 Views